Advanced Well-differentiated Neuroendocrine Tumors
1 clinical trials · Condition
◉ Watch Advanced Well-differentiated Neuroendocrine Tumors
| Record | Firm | Date |
|---|---|---|
| PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies (NCT03365791) | Novartis Pharmaceuticals | 2018-01-24 |
Track Advanced Well-differentiated Neuroendocrine Tumors automatically
Every clearance here is in the API, with alerts when new ones post.